Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

8.490 -0.030 (-0.35%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,510
Open 8.360
Bid (Size) 3.400 (2)
Ask (Size) 9.300 (1)
Prev. Close 8.520
Today's Range 8.300 - 8.500
52wk Range 5.200 - 14.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech to Participate in Jefferies Healthcare Conference
From Alvotech
Via GlobeNewswire
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
From Alvotech
Via GlobeNewswire

Performance

YTD
-15.18%
-15.18%
1 Month
-13.37%
-13.37%
3 Month
-39.10%
-39.10%
6 Month
+33.49%
+33.49%
1 Year
-24.13%
-24.13%

More News

Read More
BJ's Wholesale, Kingsoft Cloud, Zoom Video And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Earnings Scheduled For May 18, 2023
Via Benzinga
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
From Alvotech
Via GlobeNewswire
Alvotech Issues Annual Equality Report Covering 2022
From Alvotech
Via GlobeNewswire
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOW
From The Rosen Law Firm, P.A.
Via Business Wire
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
From Alvotech
Via GlobeNewswire
Lennox International, Meta Platforms, Hasbro And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
From Alvotech
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
From Alvotech
Via GlobeNewswire
Alvotech Provides Update on Corporate Sustainability Framework
From Alvotech
Via GlobeNewswire
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.